The authors regret the following errors in Table 1: Under Maintenance in column two, for RO after PDS, “Excluded” should read “Stage III excluded, stage IV permitted”. Under Maintenance in column two, for RO after IDS, “Excluded” should read “Not reported”. The corrected table appears below. The authors would like to apologise for any inconvenience caused.
Mirza, M., Coleman, R., Gonzalez-Martin, A., Moore, K., Colombo, N., Ray-Coquard, I., et al. (2021). Corrigendum to ‘The forefront of ovarian cancer therapy: update on PARP inhibitors': [Annals of Oncology 31 (2020) 1148–1159] (Annals of Oncology (2020) 31(9) (1148–1159), (S0923753420398914), (10.1016/j.annonc.2020.06.004)) [Altro] [10.1016/j.annonc.2021.05.796].
Corrigendum to ‘The forefront of ovarian cancer therapy: update on PARP inhibitors': [Annals of Oncology 31 (2020) 1148–1159] (Annals of Oncology (2020) 31(9) (1148–1159), (S0923753420398914), (10.1016/j.annonc.2020.06.004))
Colombo N.Primo
;
2021
Abstract
The authors regret the following errors in Table 1: Under Maintenance in column two, for RO after PDS, “Excluded” should read “Stage III excluded, stage IV permitted”. Under Maintenance in column two, for RO after IDS, “Excluded” should read “Not reported”. The corrected table appears below. The authors would like to apologise for any inconvenience caused.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
